|
aap reports €14.7 Million in H1 2009 Sales and an EBIT of -€0.4 Million
aap Implantate AG, a medical technology company listed in the Frankfurt Stock Exchange’s Prime Standard, realized a 10% sales decline to €14.7 million in the first half of 2009 (previous year: €16.3 million), with an EBIT at -€0.4 million (previous year: €1.7 million).
| In € million | H1/2009 | H1/2008 | Change | | Sales | 14.7 | 16.3 | -10% | | EBITDA | 1.2 | 3.3 | -64% | | EBIT | -0.4 | 1.7 | n. a. | | EBT | -0.8 | 1.3 | n. a. | | Result for the period | -1.1 | 0.9 | n.a. | | In € million | Jun. 30, 2009 | Dec. 31, 2008 | Change | | Equity (ratio) | 41.6 (65%) | 41.3 (62%) | +1% | | Balance sheet total | 64.3 | 67.0 | -4% | | Employees | 281 | 315 | -11% |
Group EBITDA in the first half of 2009 amounted to €1.2 million (previous year: €3.3 million). The Group’s EBIT was -€0.4 million (previous year: €1.7 million) and its EBT was -€0.8 million (previous year: €1.3 million). With a balance sheet total of €64.3 million (Dec. 31, 2008: €67.0 million) the equity ratio rose slightly to 65%.
Disregarding one-time income (an initial order in 2008 and a product sale in 2009), the sales decline was only 3%.
For the second half of 2009 the Management Board anticipates a recovery in demand and an improvement in sales and earnings.
aap is currently holding promising talks on granting licenses or the disposal of several products that no longer form part of its core product area. In addition, global partner companies have expressed interest in aap R&D projects.
Along with these projects and higher anticipated sales than in the fiscal year2008, the improved cash flow situation and positive results of cost reduction measures are expected to contribute toward achieving profitable growth in the fiscal year 2009.
For further information, please contact:
aap Implantate AG | | Lorenzweg 5 | | D-12099 Berlin | | X | | Biense Visser | Nanette Hüdepohl | | Director/CEO | Head of Corporate Communications and Legal Affairs | | Tel.: +49 30 750 19 - 200 | Tel.: +49 30 75019 - 133 | | Fax: +49 30 750 19 - 290 | Fax: +49 30 75019 - 290 | | X | | WKN 506660, ISIN DE0005066609 | | Prime Standard/Regulated Market | | Traded at all German Stock Exchanges |
|
Print this page
